Top

Published in:

01-12-2006 | Journal club critique

A disheartening story: Aprotinin in cardiac surgery

Authors: Marcus Lien, Eric B Milbrandt

Published in: Critical Care | Issue 6/2006

Excerpt

Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354:353–365 [1]. …

Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354: 353-365. 10.1056/NEJMoa051379CrossRefPubMed

Cosgrove DM III, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD: Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992, 54: 1031-1036.CrossRefPubMed

D'Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, Levy JH, Lynch KE, Maddi R: Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996, 112: 1081-1089. 10.1016/S0022-5223(96)70110-1CrossRefPubMed

Feindt PR, Walcher S, Volkmer I, Keller HE, Straub U, Huwer H, Seyfert UT, Petzold T, Gams E: Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995, 60: 1076-1080. 10.1016/0003-4975(95)00525-PCrossRefPubMed

Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ: Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993, 55: 1418-1424.CrossRefPubMed

Umbrain V, Christiaens F, Camu F: Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994, 8: 198-201. 10.1016/1053-0770(94)90062-0CrossRefPubMed

Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM: A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006, 46: 327-338. 10.1111/j.1537-2995.2006.00724.xCrossRefPubMed

Hughes S: Aprotinin safety again in spotlight as new study suggests increased cardiac events. Medscape Heartwire October 2, 2006 [http://www.medscape.com/viewarticle/545400]

Harris G: FDA says Bayer failed to reveal drug risk study. New York Times September 30, 2006 [http://www.nytimes.com/2006/09/30/health/30fda.html]

10.

US Food and Drug Administration: FDA Public Health Advisory: Aprotinin Injection (marketed as Trasylol).[http://www.fda.gov/cder/drug/advisory/aprotinin20060929.htm]

Title: A disheartening story: Aprotinin in cardiac surgery
Authors: Marcus Lien
Eric B Milbrandt
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: Critical Care / Issue 6/2006
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc5072

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A disheartening story: Aprotinin in cardiac surgery

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2006

Fasting and nutrient-stimulated plasma peptide-YY levels are elevated in critical illness and associated with feed intolerance: an observational, controlled study

How emergency departments might alert for prehospital heat-related excess mortality?

Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage

Ethics review: Position papers and policies – are they really helpful to front-line ICU teams?

Equipment review: Cooling catheters to induce therapeutic hypothermia?

Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure